- Home
- OCUL vs GERN Comparison
OCUL vs GERN Comparison
Compare OCUL & GERN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OCUL
- GERN
- Stock Information
- Founded
- OCUL 2006
- GERN 1990
- Country
- OCUL United States
- GERN United States
- Employees
- OCUL N/A
- GERN N/A
- Industry
- OCUL Biotechnology: Pharmaceutical Preparations
- GERN Biotechnology: Pharmaceutical Preparations
- Sector
- OCUL Health Care
- GERN Health Care
- Exchange
- OCUL Nasdaq
- GERN Nasdaq
- Market Cap
- OCUL 957.3M
- GERN 840.7M
- IPO Year
- OCUL 2014
- GERN 1996
- Fundamental
- Price
- OCUL $7.06
- GERN $1.18
- Analyst Decision
- OCUL Strong Buy
- GERN Buy
- Analyst Count
- OCUL 10
- GERN 9
- Target Price
- OCUL $16.11
- GERN $5.13
- AVG Volume (30 Days)
- OCUL 1.6M
- GERN 11.2M
- Earning Date
- OCUL 05-05-2025
- GERN 05-07-2025
- Dividend Yield
- OCUL N/A
- GERN N/A
- EPS Growth
- OCUL N/A
- GERN N/A
- EPS
- OCUL N/A
- GERN N/A
- Revenue
- OCUL $59,647,000.00
- GERN $116,293,000.00
- Revenue This Year
- OCUL $13.32
- GERN $194.54
- Revenue Next Year
- OCUL $13.13
- GERN $56.51
- P/E Ratio
- OCUL N/A
- GERN N/A
- Revenue Growth
- OCUL N/A
- GERN 22264.04
- 52 Week Low
- OCUL $4.06
- GERN $1.17
- 52 Week High
- OCUL $11.78
- GERN $5.34
- Technical
- Relative Strength Index (RSI)
- OCUL 44.18
- GERN 32.46
- Support Level
- OCUL $6.84
- GERN $1.34
- Resistance Level
- OCUL $8.90
- GERN $1.44
- Average True Range (ATR)
- OCUL 0.47
- GERN 0.10
- MACD
- OCUL -0.11
- GERN 0.00
- Stochastic Oscillator
- OCUL 10.71
- GERN 3.23
About OCUL Ocular Therapeutix Inc.
Ocular Therapeutix Inc is a biotechnology company that specializes in therapies for diseases and conditions of the eye. The company uses its proprietary hydrogel platform technology to deliver therapeutic agents to the eye. Its pipeline consists of eye medication that aims to overcome the limitations of current eye-drop-based therapies for ophthalmic diseases and conditions. Its pipeline product includes Dextenza, OTX-TIC, OTX-TKI, and OTX-IVT.
About GERN Geron Corporation
Geron Corp is a clinical-stage biopharmaceutical company focused on the research and development of cancer treatments. The company's drug in development, Imelstat, is being tested for the treatment of myelodysplastic syndromes, which are disorders of the blood, and myelofibrosis, which is a rare blood cancer affecting bone marrow. The company earns revenue through collaboration agreements, milestones, royalties, and licensing arrangements. Geron possesses various rights to this drug. The company operates as a single segment being, the development of therapeutic products for oncology.